OyaGen
focuses on the discovery, development and commercialization of pharmaceutical therapies to exploit RNA editing and DNA editing enzymes... Read moreOyaGen
focuses on the discovery, development and commercialization of pharmaceutical therapies to exploit RNA editing and DNA editing enzymes... Read more
News
Sep 18, 2023
Benzinga
OyaGen: OyaGen, Inc. announces a new publication for its COVID therapeutic in development and publication of related patents
Apr 21, 2021
Pharmabiz
OyaGen: Tonix Pharma inks pact with OyaGen to develop antiviral SARSCoV2 inhibitor, TNX3500 to treat Covid19
Apr 19, 2021
GlobalNewswire
Press Release: OyaGen : Tonix Pharmaceuticals Enters into Exclusive Worldwide Licensing Agreement with OyaGen to Develop Antiviral SARS-CoV-2 Inhibitor, TNX-3500, for the Treatment of COVID-19
Jan 07, 2021
PR Newswire
Press Release: OyaGen : Oyagen, Inc. Publishes Study On Its OYA1 As A "Highly Effective" Experimental Drug Candidate For Treating Infections By The Ebola Virus
Mar 12, 2020
Pharamceutical Technology
OyaGen: Covid-19: OyaGen assesses candidate; Airway files for testing
Mar 11, 2020
Rochester Business Journal
OyaGen: OyaGen reports progress in fight against virus
Mar 11, 2020
BioSpace
OyaGen: OyaGen, Inc. Announces a Compound in Development with Broad Antiviral Activity Against Coronaviruses, including SARS-CoV-2
Jul 26, 2018
BioPortfolio
OyaGen: OyaGen Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 10052018 Prices from USD $250
Jan 07, 2017
BioPortfolio
OyaGen: OyaGen Inc Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250
Jul 28, 2015
PR-INSIDE.COM
Press Release: OyaGen : New Market Report: OyaGen Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
OyaGen Competitors
1
2
3
4
5
6
7
8
9
10